As per attachment
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Norris Medicines' Board approved its Q3 FY26 (Dec 2025) and nine-months unaudited results on 14 Feb 2026. Revenue from operations jumped sharply to ₹326.66 lakhs in Q3 FY26, up from ₹110.60 lakhs in Q3 FY25 (roughly tripling), and nine-month revenue rose to ₹672.36 lakhs from ₹309.93 lakhs. The company swung to a quarterly profit after tax of ₹69.74 lakhs versus a loss of ₹28.17 lakhs in Q3 FY25, though the nine-month figure is still a loss of ₹33.12 lakhs (improved from a ₹100.90 lakh loss a year ago). Statutory auditor Bahedia & Associates issued a clean limited review report with no qualifications. A long-pending criminal appeal involving a ₹1.33 crore demand was finally resolved in the company's favour on 19 Nov 2025, removing a key legal overhang.
Strong topline growth and a return to quarterly profitability are positive signs, but the company remains in the red on a year-to-date basis, so investors should watch whether the momentum sustains into Q4. The favourable court order on the ₹1.33 crore demand removes a lingering contingent-liability concern for shareholders.